Scinai Immunotherapeutics Ltd. (SCNI) stock
SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Scinai Immunotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Scinai Immunotherapeutics's operating cash flow for the twelve months ending Dec 31, 2021 was -$7.43M. For fiscal 2025 it was -$6.03M. The highest annual figure on record is -$2.90M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.03M | – |
| FY2024 | Dec 31, 2024 | -$6.34M | – |
| FY2023 | Dec 31, 2023 | -$9.38M | – |
| FY2022 | Dec 31, 2022 | -$7.27M | – |
| FY2021 | Dec 31, 2021 | -$7.43M | – |
| FY2020 | Dec 31, 2020 | -$22.56M | – |
| FY2017 | Dec 31, 2017 | -$2.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2023 | Jun 30, 2023 | -$2.88M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.67M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.86M | – |
See a number that looks wrong?